Capricor Therapeutics, Inc. [NASDAQ: CAPR] disclosed the promising final data from its Phase II HOPE-II study in sufferers with Duchenne Muscular Dystrophy treated with CAP-1002. This news has sent the stock of the firm to a new level as the firm stock surged 16% at the time of writing which is good news for its investors.
The firm revealed that the HOPE-II clinical study has achieved its primary efficacy endpoint of mid-PUL v1.2 as well as various skeletal and cardiac endpoints recommending clinically relevant decelerating of disease progression. The firm has witnessed that throughout the study CAP-1002 was mostly secure and well-endured.
The importance of this data is crucial to sufferers and the DMD community. The data indicated that CAP-1002 slowed the decline of DMD in sufferers for whom few options are presently available. The data disclosed that CAP-1002 slowed the disease by 71% as per the one-year results. Moreover, the data also revealed that CAP-1002 substantially enhanced Cardiac function in victims.
Phase II HOPE-II Study
HOPE-2 was a randomized, double-blind, placebo-controlled, Phase II clinical study of the lead investigational therapy, CAP-1002, of the firm in boys and young men who have experienced DMD and are non-ambulant, the later stage of the disease process. The study was carried at nine sites across the US.
These data were recently acknowledged at this year’s World Muscle Society Virtual Congress as a late-breaking oral presentation, due to its high-impact research results that are of great interest to congress participants. The late-breaking results will be unveiled today, September 24, 2021.